🚀 VC round data is live in beta, check it out!
Suzhou Sepax Technologies Valuation Multiples
Discover revenue and EBITDA valuation multiples for Suzhou Sepax Technologies and similar public comparables like Vazyme Biotech, GemPharmatech, Oxford Nanopore Technologies, Takara Bio and more.
Suzhou Sepax Technologies Overview
About Suzhou Sepax Technologies
Suzhou Sepax Technologies Co Ltd is engaged in the Research, development and produce liquid chromatography materials for drug analysis, detection, separation and purification.
Founded
2009
HQ
Employees
N/A
Website
Financials (LTM)
EV
$1B
Suzhou Sepax Technologies Financials
Suzhou Sepax Technologies reported last 12-month revenue of $58M.
In the same LTM period, Suzhou Sepax Technologies generated $42M in gross profit and $17M in net income.
Revenue (LTM)
Suzhou Sepax Technologies P&L
In the most recent fiscal year, Suzhou Sepax Technologies reported revenue of $46M and EBITDA of $18M.
Suzhou Sepax Technologies expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $58M | XXX | $46M | XXX | XXX | XXX |
| Gross Profit | $42M | XXX | $32M | XXX | XXX | XXX |
| Gross Margin | 73% | XXX | 71% | XXX | XXX | XXX |
| EBITDA | — | XXX | $18M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 39% | XXX | XXX | XXX |
| EBIT Margin | 33% | XXX | 31% | XXX | XXX | XXX |
| Net Profit | $17M | XXX | $12M | XXX | XXX | XXX |
| Net Margin | 29% | XXX | 27% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Suzhou Sepax Technologies Stock Performance
Suzhou Sepax Technologies has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
Suzhou Sepax Technologies' stock price is $2.94.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | 0.0% | XXX | XXX | XXX | $0.03 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSuzhou Sepax Technologies Valuation Multiples
Suzhou Sepax Technologies trades at 20.5x EV/Revenue multiple, and 67.0x EV/EBITDA.
EV / Revenue (LTM)
Suzhou Sepax Technologies Financial Valuation Multiples
As of March 24, 2026, Suzhou Sepax Technologies has market cap of $1B and EV of $1B.
Equity research analysts estimate Suzhou Sepax Technologies' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Suzhou Sepax Technologies has a P/E ratio of 73.8x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 20.5x | XXX | 25.8x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 67.0x | XXX | XXX | XXX |
| EV/EBIT | 62.1x | XXX | 83.6x | XXX | XXX | XXX |
| EV/Gross Profit | 28.2x | XXX | 36.4x | XXX | XXX | XXX |
| P/E | 73.8x | XXX | 99.1x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 155.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Suzhou Sepax Technologies Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Suzhou Sepax Technologies Margins & Growth Rates
Suzhou Sepax Technologies' revenue in the last 12 month grew by 21%.
Suzhou Sepax Technologies Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 21% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 39% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 49% | XXX | XXX | XXX |
| S&M Expenses to Revenue | 12% | XXX | 4% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 28% | XXX | 5% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 14% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 40% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Suzhou Sepax Technologies Public Comps
See public comps and valuation multiples for other Life Sciences Tools comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Vazyme Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| GemPharmatech | XXX | XXX | XXX | XXX | XXX | XXX |
| Oxford Nanopore Technologies | XXX | XXX | XXX | XXX | XXX | XXX |
| Takara Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Personalis | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Suzhou Sepax Technologies M&A Activity
Suzhou Sepax Technologies acquired XXX companies to date.
Last acquisition by Suzhou Sepax Technologies was on XXXXXXXX, XXXXX. Suzhou Sepax Technologies acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Suzhou Sepax Technologies
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSuzhou Sepax Technologies Investment Activity
Suzhou Sepax Technologies invested in XXX companies to date.
Suzhou Sepax Technologies made its latest investment on XXXXXXXX, XXXXX. Suzhou Sepax Technologies invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Suzhou Sepax Technologies
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Suzhou Sepax Technologies
| When was Suzhou Sepax Technologies founded? | Suzhou Sepax Technologies was founded in 2009. |
| Where is Suzhou Sepax Technologies headquartered? | Suzhou Sepax Technologies is headquartered in China. |
| Is Suzhou Sepax Technologies publicly listed? | Yes, Suzhou Sepax Technologies is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Suzhou Sepax Technologies? | Suzhou Sepax Technologies trades under 688758 ticker. |
| When did Suzhou Sepax Technologies go public? | Suzhou Sepax Technologies went public in 2025. |
| Who are competitors of Suzhou Sepax Technologies? | Suzhou Sepax Technologies main competitors are Vazyme Biotech, GemPharmatech, Oxford Nanopore Technologies, Takara Bio. |
| What is the current market cap of Suzhou Sepax Technologies? | Suzhou Sepax Technologies' current market cap is $1B. |
| What is the current revenue of Suzhou Sepax Technologies? | Suzhou Sepax Technologies' last 12 months revenue is $58M. |
| What is the current revenue growth of Suzhou Sepax Technologies? | Suzhou Sepax Technologies revenue growth (NTM/LTM) is 21%. |
| What is the current EV/Revenue multiple of Suzhou Sepax Technologies? | Current revenue multiple of Suzhou Sepax Technologies is 20.5x. |
| Is Suzhou Sepax Technologies profitable? | Yes, Suzhou Sepax Technologies is net-income-positive (as of the last 12 months). |
| What is the current net income of Suzhou Sepax Technologies? | Suzhou Sepax Technologies' last 12 months net income is $17M. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.